User:Mr. Ibrahem/Altretamine

Mr. Ibrahem/Altretamine
Clinical data
Pronunciation	al tret' a meen
Trade names	Hexalen
Other names	Hexamethylmelamine, 2,4,6-Tris(dimethylamino)-1,3,5-triazine
AHFS/Drugs.com	Monograph
MedlinePlus	a601200
License data	US FDA: Altretamine;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth (capsules)
Drug class	Alkylating agent
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only;
Pharmacokinetic data
Protein binding	94%
Metabolism	Extensive liver
Metabolites	Pentamethylmelamine, tetramethylmelamine
Elimination half-life	4.7–10.2 hours
Identifiers
	IUPAC name N2,N2,N4,N4,N6,N6-Hexamethyl-1,3,5-triazine-2,4,6-triamine;
Chemical and physical data
Formula	C9H18N6
Molar mass	210.285 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n1c(nc(nc1N(C)C)N(C)C)N(C)C;
	InChI InChI=1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3 ; Key:UUVWYPNAQBNQJQ-UHFFFAOYSA-N ;
	(verify)

Altretamine, sold under the brand name Hexalen, is a medication used to treat ovarian cancer.^[1] Specifically it is used for advanced disease when other treatments are not effective.^[1] It is taken by mouth.^[1]

Common side effects include nausea, vomiting, diarrhea, hair loss, bone marrow suppression, peripheral nerve problems, and rash.^[1] Other side effects may include mood disorders and further cancer.^[2] Use in pregnancy may harm the baby.^[2] It is an alkylating agent.^[1]

Altretamine was approved for medical use in the United States in 1990.^[1] As of 2022 it is not commercially available in the United States.^[3]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Altretamine". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 6 May 2021. Retrieved 14 January 2022.
^ ^a ^b "Altretamine Monograph for Professionals". Drugs.com. Archived from the original on 26 January 2021. Retrieved 14 January 2022.
^ "Drugs@FDA: FDA-Approved Drugs". www.accessdata.fda.gov. Archived from the original on 27 August 2021. Retrieved 14 January 2022.

[Liv2022-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Altretamine". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 6 May 2021. Retrieved 14 January 2022.

[AHFS2022-2] "Altretamine Monograph for Professionals". Drugs.com. Archived from the original on 26 January 2021. Retrieved 14 January 2022.

[3] "Drugs@FDA: FDA-Approved Drugs". www.accessdata.fda.gov. Archived from the original on 27 August 2021. Retrieved 14 January 2022.

[1]

[2]

[3]